Kiniksa Pharmaceuticals International, plc
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $677.6M | $423.2M | $270.3M | $220.2M | $38.5M |
| Cost of revenue | $77.7M | $60.9M | $33.4M | $22.9M | $9.1M |
| Selling, general & administrative | $196.3M | $168.0M | $129.4M | $98.0M | $85.9M |
| Research and development | $96.9M | $111.6M | $76.1M | $65.5M | $99.3M |
| Operating income | $77.2M | -$45.6M | -$25.2M | $9.8M | -$156.6M |
| Pretax income | $88.9M | -$36.2M | -$16.7M | $11.0M | -$156.5M |
| Income tax expense | $29.9M | $7.0M | -$30.7M | -$172.3M | $1.4M |
| Net income | $59.0M | -$43.2M | $14.1M | $183.4M | -$157.9M |
| Balance Sheet | |||||
| Cash and equivalents | $165.6M | $183.6M | $108.0M | $122.7M | $122.5M |
| Current assets | $527.2M | $331.8M | $276.3M | $243.1M | $196.4M |
| Total assets | $763.6M | $580.6M | $526.3M | $459.7M | $232.8M |
| Current liabilities | $139.2M | $100.6M | $63.7M | $47.1M | $44.8M |
| Total liabilities | $196.0M | $142.1M | $87.5M | $63.5M | $47.8M |
| Stockholders' equity | $567.6M | $438.4M | $438.8M | $396.1M | $185.0M |
| Cash Flow Statement | |||||
| Cash from operations | $138.0M | $25.7M | $13.3M | $5.8M | -$126.3M |
| Depreciation and amortization | $196,000 | $448,000 | $1.1M | $1.2M | $1.5M |
| Stock-based compensation | $37.0M | $30.7M | $27.1M | $25.1M | $25.2M |
| Capital expenditure | $1.6M | $277,000 | $130,000 | $105,000 | $415,000 |
| Free cash flow | $136.4M | $25.4M | $13.2M | $5.7M | -$126.7M |
| Impairments | $0 | — | — | — | — |
Shares outstanding 76.9M · Free float 40.9%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.